Press release: Medterra CBD
Medterra CBD on October 1 announced its leading line of pet products has been approved by the National Animal Supplement Council (NASC). A global leader in the CBD space, Medterra CBD launched its pet products earlier this year, including beef, chicken and unflavored tinctures, as well as joint support pet chews.
Formed in 2001, the NASC is a nonprofit industry group dedicated to protecting and enhancing the health of companion animals throughout the United States by identifying the highest quality products in the animal health supplement industry.
“To qualify for NASC membership a company must sign a written agreement to adhere to our comprehensive quality requirements. Medterra demonstrates their commitment to these objectives by their ‘seed to sale’ quality philosophy that is not just articulated, but is also evidenced in the actions of their company,” said Bill Bookout, NASC president. “We welcome Medterra as a new member that will help continue to shape the future of the cannabis industry for the benefit of companion animals.”
The announcement comes just off the heels of Medterra’s recent partnership with Chuck Latham Associates Inc. (CLA), which allows the company’s pet products to be distributed throughout the organization’s network of retailers, manufacturers, and distributors in the pet specialty, veterinary, and farm stores industries. Made up of over 1,000 pet experts coast to coast, CLA is the premier pet specific sales and marketing agency for nearly three decades.
“The missions of both the NASC and CLA are very similar to ours,” said Jason Dorfman, vice president, pet, Medterra CBD. “Providing products that are of the highest quality and backed by research are at the center of all that we do.”
Laddering up to the company’s commitment to the pet care category, Medterra also recently commissioned Baylor College of Medicine to conduct clinical trials on its pet products with outpatient senior dogs suffering from arthritis to measure the efficacy of its products. As a result, the study found that 80 percent of participating dogs experienced some level of benefit, including an increase in willingness to play and run, and ease in lying and standing after using Medterra’s pet products.
Though CBD has been available for sale in the U.S. for the past four years, Medterra CBD’s focus on scientific validation is unique in the category, and a departure from sole reliance on testimonial and anecdotal reviews of products often seen with much of the CBD industry.